ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Northwest Biotherapeutics, Inc. (“Northwest Bio” or the “Company”) (NASDAQ: NWBO) and/or certain of its officers complied with the federal securities laws in making public statements regarding its experimental cancer vaccine, DCVax-Direct. On June 19, 2014, TheStreet.com published a report in which Dr. Aman Buzdar is quoted as criticizing Northwest Bio for issuing a series of public statements regarding preliminary results of its ongoing DCVax-Direct clinical trial. Dr. Buzdar is the vice president of clinical research at MD Anderson, which is conducting the clinical trial. The price of Northwest Bio stock has declined significantly on the report.
If you recently purchased NWBO common stock and have suffered loss on that investment, you are encouraged to contact Holzer & Holzer, LLC and its attorney Marshall P. Dees, Esq. via email at email@example.com, or via toll-free telephone at (888) 508-6832, to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.